We are pleased to announce a strategic partnership between Upfront Diagnostics, a UK-based MedTech company dedicated to transforming stroke care through innovative diagnostic solutions, and the Vingmed Group, a leading distributor of advanced medical equipment in the Nordic region.
Upfront Diagnostics has developed LVOne, the world’s first rapid blood test designed to help identify large vessel occlusion (LVO) strokes at the point of care within minutes and improve triage decisions in the pre-hospital setting. Using innovative biomarkers, emergency teams are enabled to rapidly assess patients and identify those most likely to benefit from specialist interventions, reduce delays to treatment and consequently improve outcomes for patients experiencing acute neurological emergencies.
By combining Upfront Diagnostics’ technological innovation with Vingmed Group’s market expertise and distribution capabilities, this partnership will accelerate access to advanced healthcare solutions across the Nordic region.
The collaboration also strengthens Vingmed’s offering within emergency and acute care diagnostics, enabling healthcare professionals to access innovative technologies that can contribute to clinical decision-making and improved patient pathways.
“We are proud to partner with Upfront Diagnostics and add LVOne to our portfolio of innovative acute care solutions. This collaboration strengthens our commitment to providing healthcare professionals with technologies that support faster clinical decision-making and improved patient care, particularly in time-critical conditions such as stroke,” said Kolbjørn Haarr, CEO, Vingmed Group.
“We are thrilled to bring LVOne to patients across the Nordics, and proud to do so alongside Vingmed, a leading name in medical device distribution. This is a hugely important partnership for us, and a major step towards making rapid stroke diagnosis a standard of care worldwide,” said Gonzalo Ladreda, CEO and Co-founder, Upfront Diagnostics.
Under the agreement, Vingmed will serve as the authorised distributor for LVOne. The partnership is designed to decentralise stroke testing and reduce time to thrombectomy, bringing specialist-level triage capability closer to the patient at the earliest possible stage of care.
This partnership with Vingmed forms part of Upfront Diagnostics’ broader EU distribution strategy, supporting the global commercialisation of LVOne and the company’s mission to make rapid, decentralised stroke diagnosis a standard of care.
